Lyra therapeutics to present additional lantern phase 2 study results for lyr‑210 in two oral presentations at ars annual meeting

Watertown, mass. , aug. 29, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today announced that the company will present additional phase 2 results from the lantern study for lyr‑210, the company's lead product candidate for chronic rhinosinusitis, at the 68th annual meeting of the american rhinologic society (ars), taking place september 9-10, 2022 in philadelphia.
LYRA Ratings Summary
LYRA Quant Ranking